Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2893432 | 0.93 | MEN1 (0.48) | MEN1KMT2ANCOA1NCOA3GRM1 | |
| SCHEMBL2895632 | 0.91 | MEN1 (0.48) | MEN1KMT2AGRM1L3MBTL1LMNA | |
| SCHEMBL3422930 | 0.90 | MEN1 (0.53) | MEN1KMT2ANCOA1NCOA3GRM1 | |
| SCHEMBL3415346 | 0.89 | MEN1 (0.50) | MEN1KMT2AGRM1L3MBTL1LMNA | |
| SCHEMBL2893352 | 0.87 | MEN1 (0.57) | MEN1KMT2AGRM1L3MBTL1MAPT | |
| SCHEMBL2893613 | 0.87 | MEN1 (0.53) | MEN1KMT2AGRM1L3MBTL1STAT3 | |
| SCHEMBL2893475 | 0.85 | MEN1 (0.47) | MEN1KMT2AGRM1L3MBTL1LMNA | |
| SCHEMBL2895790 | 0.83 | SMN1; SMN2 (0.51) | MEN1KMT2AL3MBTL1LMNAMAPT | |
| SCHEMBL2887735 | 0.82 | STAT3 (0.47) | MEN1KMT2AGRM1L3MBTL1STAT3 | |
| SCHEMBL3418594 | 0.82 | MEN1 (0.53) | MEN1KMT2AGRM1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | 4SC AG (DE) | 2010-11-11 | — | — | US | claimed |
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | 4SC AG (DE) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, CCAR2, BCL2 | MEN1 4556/4885KMT2A 2606/4885NCOA1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.